Terms: = Prostate cancer AND ATP1A1, P05023, MGC51750, MGC3285, ENSG00000163399, 476
125 results:
1. prostate-specific membrane antigen (PSMA) glycoforms in prostate cancer patients seminal plasma.
Mackay S; Oduor IO; Burch TC; Troyer DA; Semmes OJ; Nyalwidhe JO
Prostate; 2024 Apr; 84(5):479-490. PubMed ID: 38151791
[TBL] [Abstract] [Full Text] [Related]
2. Risk of cancer in acromegaly patients: An updated meta-analysis and systematic review.
Xiao Z; Xiao P; Wang Y; Fang C; Li Y
PLoS One; 2023; 18(11):e0285335. PubMed ID: 38032888
[TBL] [Abstract] [Full Text] [Related]
3. Secondary Primary cancer Risk After Radiation Therapy in Rectal cancer: A Population-Based Cohort Study With Propensity Score Matching.
Schlesinger-Raab A; Schubert-Fritschle G; Kim M; Werner J; Belka C; Wolff H; Agha A; Fuchs M; Friess H; Combs S; Häussler B; Engel J; Halfter K
Clin Colorectal Cancer; 2023 Dec; 22(4):485-495.e3. PubMed ID: 37838522
[TBL] [Abstract] [Full Text] [Related]
4. prostate cancer: Under-representation of African American Men in Research Studies Used in the Latest NCCN Guidelines.
Lubarsky R; Ambinder D; Barnett J; Choudhury M; Saji A; Fishman AI; Fullerton S; Phillips JL
Urology; 2023 Oct; 180():28-34. PubMed ID: 37479145
[TBL] [Abstract] [Full Text] [Related]
5. Impact of Asian Race on Prognosis in De Novo Metastatic prostate cancer.
Ni X; Luu M; Ma W; Zhang T; Wei Y; Freedland SJ; Ye D; Daskivich TJ; Zhu Y
J Natl Compr Canc Netw; 2023 Jul; 21(7):733-741.e3. PubMed ID: 37433430
[TBL] [Abstract] [Full Text] [Related]
6. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Sweeney CJ; Martin AJ; Stockler MR; Begbie S; Cheung L; Chi KN; Chowdhury S; Frydenberg M; Horvath LG; Joshua AM; Lawrence NJ; Marx G; McCaffrey J; McDermott R; McJannett M; North SA; Parnis F; Parulekar W; Pook DW; Reaume MN; Sandhu SK; Tan A; Tan TH; Thomson A; Vera-Badillo F; Williams SG; Winter D; Yip S; Zhang AY; Zielinski RR; Davis ID;
Lancet Oncol; 2023 Apr; 24(4):323-334. PubMed ID: 36990608
[TBL] [Abstract] [Full Text] [Related]
7. Direct Comparison of Two Different Definitions with Biochemical Recurrence after Low-Dose-Rate Brachytherapy for prostate cancer.
Takeuchi S; Iinuma K; Nakane K; Nakano M; Kawase M; Kawase K; Takai M; Kato D; Mori T; Takano H; Kumano T; Matsuo M; Koie T
Curr Oncol; 2023 Feb; 30(3):2792-2800. PubMed ID: 36975425
[TBL] [Abstract] [Full Text] [Related]
8. Potential plasma microRNAs signature miR-190b-5p, miR-215-5p and miR-527 as non-invasive biomarkers for prostate cancer.
Khan MM; Serajuddin M; Bharadwaj M
Biomarkers; 2023 Mar; 28(2):227-237. PubMed ID: 36644827
[No Abstract] [Full Text] [Related]
9. Variations in Age-Adjusted prostate cancer Incidence Rates by Race and Ethnicity After Changes in prostate-Specific Antigen Screening Recommendation.
Lai SM; Keighley J; Garimella S; Enko M; Parker WP
JAMA Netw Open; 2022 Nov; 5(11):e2240657. PubMed ID: 36342715
[TBL] [Abstract] [Full Text] [Related]
10. cancer Survivors' Long-Term Health Service Costs in Queensland, Australia: Results of a Population-Level Data Linkage Study (Cos-Q).
Merollini KMD; Gordon LG; Ho YM; Aitken JF; Kimlin MG
Int J Environ Res Public Health; 2022 Aug; 19(15):. PubMed ID: 35954835
[TBL] [Abstract] [Full Text] [Related]
11. Multiple primary melanoma in association with other personal and familial cancers.
Yang X; Karapetyan L; Huang Z; Knight AD; Rajendran S; Sander C; Minnier CP; Wilson MJ; Kirkwood JM
Cancer Med; 2023 Feb; 12(3):2474-2483. PubMed ID: 35932099
[TBL] [Abstract] [Full Text] [Related]
12. Strategies to improve cost effectiveness of robotic assisted laparoscopic radical prostatectomy in emerging economies.
Caicedo JI; Santander J; Taborda A; Medina C; Zuluaga L; Trujillo CG; Castillo CB; Londoño Trujillo D; Plata M
J Robot Surg; 2023 Feb; 17(1):243-250. PubMed ID: 35668314
[TBL] [Abstract] [Full Text] [Related]
13. Catalase C262T genetic variation and cancer susceptibility: A comprehensive meta-analysis with meta-regression and trial sequential analysis.
Barek MA; Jafrin S; Aziz MA; Islam MS
Int J Biol Markers; 2022 Sep; 37(3):227-240. PubMed ID: 35645161
[TBL] [Abstract] [Full Text] [Related]
14. Long-term outcomes of whole gland high-intensity focused ultrasound for localized prostate cancer.
Lo Verde K; Toledano H; Campagna J; Rossi D; Bastide C; Baboudjian M
Int Urol Nephrol; 2022 Jun; 54(6):1233-1238. PubMed ID: 35397077
[TBL] [Abstract] [Full Text] [Related]
15. Conventional dose versus dose escalated radiotherapy including high-dose-rate brachytherapy boost for patients with Gleason score 9-10 clinical localized prostate cancer.
Yamazaki H; Suzuki G; Aibe N; Shimizu D; Kimoto T; Masui K; Yoshida K; Nakamura S; Okabe H
Sci Rep; 2022 Jan; 12(1):268. PubMed ID: 34997125
[TBL] [Abstract] [Full Text] [Related]
16. Men's preferences for image-guidance in prostate radiation therapy: A discrete choice experiment.
Brown A; Pain T; Tan A; Anable L; Callander E; Watt K; Street D; De Abreu Lourenco R
Radiother Oncol; 2022 Feb; 167():49-56. PubMed ID: 34890737
[TBL] [Abstract] [Full Text] [Related]
17. Effect of vesicourethral anastomosis technique on functional results in retropubic radical prostatectomy.
Kızılay F; Kalemci S; Şimşir A
Int J Clin Pract; 2021 Sep; 75(9):e14460. PubMed ID: 34105852
[TBL] [Abstract] [Full Text] [Related]
18. Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant prostate cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival.
Maj-Hes A; Szarvas T; Sevcenco S; Kramer G
Adv Ther; 2021 Jul; 38(7):3831-3841. PubMed ID: 34043207
[TBL] [Abstract] [Full Text] [Related]
19. Safety of image-guided radiotherapy in definitive radiotherapy for localized prostate cancer: a population-based analysis.
Kuo YH; Liang JA; Chen GH; Li CC; Chien CR
Br J Radiol; 2021 May; 94(1121):20200456. PubMed ID: 33861622
[TBL] [Abstract] [Full Text] [Related]
20. Patients' preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuation.
Rentz AM; Mansukhani SG; Liu J; Lloyd AJ; Heidenreich S; Matza LS; Dawson NA; Shore N; Freedland SJ
Urol Oncol; 2021 Jun; 39(6):367.e7-367.e17. PubMed ID: 33736976
[TBL] [Abstract] [Full Text] [Related]
[Next]
